Helicobacter pylori a high priority for antibiotic research and development. However, there are no clear data on the global distribution of resistance or its clinical effects. We performed a systematic review and metaanalysis to assess the distribution of H pylori resistance to commonly used antibiotics and to measure the association between antibiotic resistance and treatment failure.
Helicobacter pylori (HP) infection is one of the most common chronic bacterial infections in humans, affecting approximately 4.4 billion individuals worldwide. 1 Reports of infection prevalence rates range widely among geographic regions, reaching the highest levels in developing countries and showing a well-established relationship with socioeconomic status and hygiene conditions. 1,2 HP infection causes chronic progressive gastric inflammation and a variety of diseases, including gastric and duodenal ulcers and gastric cancer. 3 In 1994 and 2009 the International Agency for Research on Cancer classified HP as a Group 1 carcinogen on the basis of a thorough review of relevant laboratory and epidemiological studies. 4 Gastric cancer is the fifth most common malignancy and the third leading cause of cancer-related morbidity globally, constituting 9% of all cancer-related mortality. 5, 6 Eradication of HP infection has been proven to reduce the incidence of gastric cancer. 7, 8 The efficacy of the HP eradication treatment has decreased dramatically because of antibiotic resistance. 9, 10 With rare exceptions, worldwide clarithromycin-containing regimens are no longer suitable for unconditional empiric use because of inadequate eradication rates (<80%). 11, 12, 13 Of even more concern, the efficacy of available alternatives (such as quadruple, sequential, concomitant, and levofloxacin-containing triple regimens) has varied greatly, 14, 15 and, although the most recent international consensus reports strongly recommend the selection of treatment based on local resistance patterns, HP testing is rarely performed. 3, 16 M A N U S C R I P T
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Items for Systematic Reviews and Meta-Analyses Protocols) statement. 18 Literature published between January 2007 and June 2017 was systematically identified in PubMed using the following search terms: "(Helicobacter pylori) AND (antibiotic OR antimicrobial OR anti-microbial OR antibacterial OR anti-bacterial OR drug)) AND (resistance OR resistant*)". No restriction on study type or population type was applied. The search was restricted to studies published in English. References of included studies and previous systematic reviews on the topic were also inspected to include relevant publications. We included studies reporting data on prevalence of primary or secondary resistance of HP to the following antibiotics: clarithromycin, metronidazole, tetracycline, amoxicillin, levofloxacin, or ciprofloxacin. Exclusion criteria were studies reporting prevalence data on fewer than 50 isolates, studies reporting prevalence of resistance expressed only as a percentage with no mention of the total number of isolates, and studies not reporting the time frame or clustering data across a time period longer than three years. Data reported within guidelines, conference presentations and letters without formal publication were also omitted. Duplicate publications or studies reporting data on the same cohort were used once by including only the most recently published data. Data on both single and combined resistance were extracted.
Definitions
Patients were defined as infected by HP if they tested positive by any of the following tests: histology, culture, serology, stool antigen, urea breath test, or rapid urease test. Prevalence of resistance was based on culture results and expressed as the number of resistant isolates divided by the total number of isolates tested. We selected 15% as the threshold for high resistant rate in accordance with the most recent international guidelines. 3, 16 Results from both phenotypic (E test, agar dilution) and genotypic (nucleic acid-based) tests were accepted for the definition of resistance. Primary resistance was defined as resistance to any antibiotic before the start of the first eradication treatment; secondary resistance was defined as resistance to any antibiotic in patients who had already undergone at least one unsuccessful eradication attempt. Response to treatment was evaluated on the basis of invasive (culture negative after gastric biopsy) and noninvasive tests.
Data extraction
A two-step selection process was conducted. The first selection of relevant studies was performed by inspection of titles and abstracts by a single reviewer (A.S.); full texts of relevant studies were retrieved and evaluated independently by two reviewers (A.S., E.C.). Data from included studies were extracted inde- 
Quality assessment
The quality of the included studies was assessed by two reviewers (A.S, E.C.) independently, using an adapted version of the tool proposed by the Joanna Briggs Institute for critical appraisal of prevalence stud- Table 1 ). 19 A score ranging from 0 to 8 points was attributed to each study (>5 points:
ies (Supplementary
high quality, 4-5 points: medium quality, <4 points: low quality). A third reviewer (E.T.) adjudicated in any case of disagreement. The need for arbitration and reason were reported in the data collection tool.
Data analysis and synthesis
Categorical variables were coded and recorded accordingly. Continuous numerical variables were reported as percentages or as means with standard deviation, and skewed numerical variables as median with interquartile range (IQR). Meta-analysis of proportions was conducted by pooling primary and secondary prevalence data using a random-effect model and grouped according to WHO regions (www.who.org; Supplementary Figure 1 ). We hypothesized the existence of substantial heterogeneity among studies due to different geographic origin and design. Between-study variability was measured with the I 2 statistic. Considerable heterogeneity was reported for a value of I 2 > 75%. 20 Any source of variability was assessed by grouping results according to predefined categorical variables. Pooled estimates were stratified by study country, study period (2006-2008, 2009-2011, 2012-2016) , and age groups (adults/children). Presence of publication bias was assessed by visually inspecting the funnel plot of the overall effect size (HP primary resistance to clarithromycin) against its standard error and tested for significance with the Egger's test. P-value <0.05 was regarded as significant. The association between treatment failure and selected antibiotic resistances was measured by computing the study odds of failing the treatment in patients with resistant strains compared to 
Results
A total of 1600 citations were identified in the initial search, and five additional records were retrieved by inspecting the references of previous systematic reviews. By applying inclusion and exclusion criteria, 178 studies were selected for analysis ( Figure 1 ). Publication bias was assessed for 104 studies (Supplementary Figure 6 ). The analysis showed visual asymmetry of the funnel plot and a significant Egger's test (p<0.01).
Arbitration of the senior author was recorded only for two studies. Forty-two studies (24%) were randomized controlled trials (RCTs), and 136 (76%) were observational studies (118 prospective and 18 retrospective).
The studies were conducted in 65 countries, mainly in the Western Pacific Region (WPR) (66, 37%) and in the European Region (EUR) (58, 33%). Table 1 summarizes the geographic distribution of the studies.
The final analysis included 66142 samples (99.5% endoscopic gastric or duodenal biopsies). Our analysis included 53583 patients, with a median age of 48 years (IQR 43-51) and approximately equal gender distribution (mean prevalence of males = 49% ± 9%). Six studies did not report the characteristics of the included population. The studies included mostly adults (45021 patients were older than 18 years) with only 16% of the studies including children. The patients' demographic and clinical features are summarized in Supplementary Table 2 .
Antibiotic resistance was assessed in 29094 (54%) naive patients and in 5676 (11%) previously treated ones. The presence of upper gastrointestinal symptoms was the most common indication for undergoing endoscopic procedure (97% of patients) and non-ulcer dyspepsia the most frequent diagnosis after endoscopy (70% of patients). In most (144, 81%) studies antibiotic resistance was detected by using culture-based methods (E test in 102 studies and agar dilution in 42). In 29 (16%) studies antibiotic resistance was assessed by molecular-based tests while in five studies the diagnostic test was not specified.
Most (158, 89%) studies specified the minimum inhibitory concentration (MIC) values used for defining resistance. Clarithromycin breakpoint ranged from 0.5 to 1 mg/dL in 87% of the studies, metronidazole breakpoint was 8 mg/dL in 94% of the studies, levofloxacin breakpoint was 1 mg/dL in 68% of the studies and 2 in
, and amoxicillin breakpoint ranged from 0.12 to 8 mg/dL (83% of the studies reported MIC between 0.25 and 1 mg/dL).
Quality assessment
Disagreement on quality of the studies and need for arbitration was recorded for three studies. The quality was high in 53 (30%) studies, medium in 93 (52%) studies, and low in 31 (18%) studies. The main factors limiting overall study quality were the low representativeness of the included population (85% single-center studies with limited sample size) and poor reporting of patients' demographic and endoscopic characteristics.
Conversely, microbiological methods for resistance testing were adequate in all studies reporting the information (93%). A full description of the diagnostic methods and specification of MIC breakpoints was provided in 88% (158) of the studies.
Pooled prevalence of HP primary resistance
The prevalence of primary clarithromycin resistance was >15% in EUR (18%, 95% CI [16] [17] [18] [19] [20] , in the Eastern Only three studies provided prevalence data for the Africa Region (AFR), not allowing the stratification according to resistance type but only overall estimates. Pooled primary resistance prevalence by WHO region is shown in Table 2 . 
Pooled prevalence of HP secondary resistance
ithromycin and metronidazole reached 18% (95% CI [16] [17] [18] [19] [20] in EUR. Pooled secondary resistance prevalence by WHO region is shown in Table 2 .
Analysis of trend
In SEAR, clarithromycin resistance significantly increased from 13% (95% CI [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Figure 2 and Supplementary Table 6 .
Ten countries provided data for WPR. Clarithromycin resistance was ≥15% in 7/10 countries; the highest rates were recorded in Australia (96%, 95% CI 92-99) and Vietnam (63%, 95% CI 37-88 The prevalence of resistance to amoxicillin or tetracycline was <5% in all countries except Vietnam, where tetracycline resistance was 17% (95% CI 4-31). Pooled estimates of antibiotic resistance by country are shown in Figure 2 and Supplementary Table 8 .
In AFR, AMR, EMR, and SEAR, less data were available, and the data were not distributed homogeneously across the countries (Table 1) . Only three studies provided data for AFR. In SEAR most studies originated from Thailand. In AMR, the most observations came from South America while North America was scarcely
represented. In EMR, almost all studies originated from Iran. A summary of pooled prevalence of antibiotic resistance by country in AFR, AMR, EMR, and SEAR is shown in Figure 2 and in Supplementary Tables 3,   4 , 5 and 7.
Age. Subgroup analysis by age group showed higher rates of antibiotic resistance in the adult population compared to children. An opposite tendency was detected in AMR for metronidazole resistance (40% in children versus 22% in adults), in EMR for metronidazole resistance (81% versus 61%) and levofloxacin resistance (29% versus 18%), and in WPR for clarithromycin resistance (85% versus 32%). Details of subgroup analysis by age group are shown in Table 4 .
Diagnostic method.
Clustering results by diagnostic method (genotypic versus phenotypic) showed no significant difference in antibiotic resistance prevalence (data not shown).
Heterogeneity assessment
Considerable heterogeneity was detected between the studies in all the analyses pooling clarithromycin, metronidazole, and levofloxacin resistance rates (I 2 >75%). Within all the subgroup analyses conducted, we detected a relevant reduction (<75%) of I 2 when grouping the studies by country of origin. The results of the heterogeneity assessment by country are displayed in Supplementary Table 9 . No relevant reduction of heterogeneity was detected when grouping results according to other relevant variables such as patient age, diagnostic method, or study quality.
Secondary outcome
Forty-five studies provided data for the secondary analysis. Among these 30 (68%) were RCTs, and 15 (32%) had an observational design. The secondary analysis included 13707 isolates, cultured from the same number of patients before starting HP eradication. Sixty percent of the included patients (8296) were naive to HP therapy. Administered therapies varied widely according to antibiotic associations, dosages, anti-acid combination, treatment schemes and duration. Among these, 35 (38%) were triple regimens (proton pump inhibitor plus two of the following antibiotics: clarithromycin, metronidazole, amoxicillin, levofloxacin), 23
(25%) were concomitant regimens (with an equal distribution between bismuth quadruple and non-bismuth quadruple regimens), and 31 (34%) were sequential regimens. Four (3%) regimens were dual therapy. Due to the high number of treatment schemes a subgroup analysis was not possible.
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A statistically significant association between eradication treatment failure and resistance detected before treatment was observed for all the antibiotics. Patients with clarithromycin-resistant HP infections had a risk of failing eradication seven-fold (OR 6.97 95% CI 5.23-9.28, P<0.001) higher than patients with susceptible strains when treated with a clarithromycin-containing regimen. A strong association was also observed for 5 ).
Discussion
Our study shows that in most WHO regions pooled prevalence of both primary and secondary resistance of HP to clarithromycin, metronidazole, and levofloxacin is higher than 15%, the common threshold for choosing alternative empiric regimens. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Metronidazole resistance is the most prevalent pattern of resistance worldwide. Both primary and secondary resistance are, in fact, well above the threshold, with the highest level recorded in the Eastern areas of the world (EMR 56% and 65%, SEAR 51% and 44%, WPR 47% and 62%). The resistance rates to clarithromycin, metronidazole, and levofloxacin have increased over time in all WHO regions. In particular, a significant increase of resistance to clarithromycin occurred in SEAR (from 13% in 2006-2008 to 21% in 2012-2016) and to levofloxacin in WPR (from 12% in 2006-2008 to 31% in 2012-2016), crossing the intervention threshold in 10 years. We also observed that the resistance rates are higher in previously treated individuals than in patients who never received eradication treatment and higher in adults than in children. We described a clear significant association between antibiotic resistance and treatment failure as secondary outcome. rates for clarithromycin, metronidazole, fluoroquinolones, amoxicillin, and tetracycline were 12%, 53%, 15%, 4%, and 6%, respectively. 22 Taking into account that almost all studies contributing to our pooled data for AMR derived from South America, our findings confirm these resistance rates.
Kuo et al provided an overview of primary antibiotic resistance prevalence in the past 25 years in the Asia-Pacific region. 13 This meta-analysis, published in 2017, included 162 studies analyzing data from 37219 patients mainly from WPR. In the time period 2006-2015, clarithromycin and metronidazole primary resistance reached 20% and 47%, respectively; the levofloxacin primary resistance rate was 21%, and both tetracycline and amoxicillin primary resistance rates were 3%. 13 In WPR we reported the same resistance rate to metronidazole (47%), similar resistance rates to levofloxacin (22%), amoxicillin (1%) and tetracycline (2%), and a higher resistance rate to clarithromycin (34%).
In the subgroup analysis by time period, we detected in general a trend of increased resistance to all the antibiotics. A significant increase in resistance over time was recorded for all antibiotics in SEAR and for levofloxacin in WPR. The same tendency was described by Kuo et al. for clarithromycin, metronidazole, and levofloxacin in the time period of 2006-2015 in the Asia-Pacific region. 13 Antibiotic resistance prevalence data in children are scarce. In our meta-analysis, 23 studies could provide clustered data by age group. In a meta-analysis of six studies published in 2017 in the Iranian pediatric population, the prevalence of resistance to clarithromycin, metronidazole, and fluoroquinolones was 12%, 71%, and 16%, respectively. 23 Our pooled estimates on children in the EMR region confirm similar rates of resistance. Although fluoroquinolones are contraindicated for the treatment of any infection in children, the resistance rate to levofloxacin was remarkable in EMR (29%) and WPR (17%), possibly reflecting resistance in the infecting strain and intrafamilial spread of quinolone-resistant isolates from adults. 24, 25 As for the high rate of metronidazole resistance in children from AMR, it is important to underline that two out of three studies contributing to the analysis for this region were conducted in Brazil where high prevalence of selfmedication of antibiotics has been observed in children and adolescents. 26 The alarming global levels of HP resistance in treatment-naive patients can be correlated with the increasing and uncontrolled consumption of antibiotics that are commonly used in HP empirical therapy and also used M A N U S C R I P T
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13 to treat other common infections in the general population (e.g., respiratory, genital, and urinary infections, parasite infestation). 27 For example, in the time period 2000-2010, global macrolide consumption increased by 19% and fluoroquinolone consumption by 64%. 28 The highest primary resistance rate registered for metronidazole and levofloxacin in the Western areas of the world likely relates to the massive use of metronidazole to treat parasite infestations in developing countries and to the increased consumption of fluoroquinolones in these regions. 13, 27 Beyond the widely proven relationship between antibiotic consumption and development of resistance, it has been recently demonstrated that the previous use of macrolides correlates directly to HP eradication failure. In one study in which a clarithromycin-containing regimen was used, the eradication failure rate was significantly higher in patients with a history of previous macrolide use for longer than two weeks than in patients with a shorter antibiotic duration. 29 A recent study from Korea demonstrated that the regions that suffered the most significant fail in eradication rates were those with the highest macrolide prescriptions. 30 Antibiotic resistance is the major driver of eradication failure. The expected efficacy of standard triple regimen (STT) has dropped to insufficient levels in many areas of the world, causing this regimen to be no longer considered appropriate for unconditional empiric use. 11, 12 Moreover, the alternative regimens suggested for overcoming clarithromycin resistance have shown heterogeneous efficacy results strongly correlated to the resistance profile of the antibiotics included. 15, 31, 32 In the analysis of the secondary outcome, our meta-analysis summarized data from 45 RCTs, and we confirmed a clear association between HP resistance and treatment failure. In particular, patients harboring clarithromycin-resistant strains had seven-fold probability of failing eradication with a clarithromycin-containing regimen. For levofloxacin resistance and combined (clarithromycin plus metronidazole) resistance, the risks are eight and nine-fold, respectively.
Our data in the Asia-Pacific region were consistent with those from Kuo et al., who reported efficacy of clarithromycin-based triple therapy <80% in countries where clarithromycin resistance was >20%. In addition, the efficacy of sequential therapy and of concomitant therapy was also <80% in most countries with clarithromycin resistance >20%. 13 The meta-analysis of Nyssen et al. highlighted that in the subgroup of clarithromycin-resistant strains, both sequential treatment and STT did not achieve satisfactory eradication rates (mean efficacy: 75% versus 43%, respectively). 15 Levofloxacin resistance also seems to play an important role in determining treatment failure. In the meta-analysis by Chen et al., the efficacy of levofloxacin triple regimen was significantly higher for levofloxacin-susceptible strains than for resistant strains (eradication rate: 81.1% versus 36.3%, risk ratio 2.38, 95% CI 1.6-3). 32 Furthermore, we showed a slightly lower risk of treatment failure in patients with metronidazole-resistant HP infection treated with metronidazole-containing regimens, consistent with the previously described data suggesting that the impact of metronidazole re-M A N U S C R I P T
sistance is less than that of clarithromycin and levofloxacin resistance because it can partially be overcome by increasing the dose and duration of treatment, especially when used a part of a bismuth-containing quadruple therapy. 3, 33, 35 The resistance in previously treated individuals is generally higher than in naive patients for almost all included antibiotics. No previous pooled data on secondary antibiotic resistance are available in the literature for making a comparison.
The results of our meta-analysis should be also considered for the possible impact on the incidence of gastric cancer. Based on GLOBOCAN estimates, the highest incidence of gastric cancer is in Western Asia (China, Japan and Korea) where antibiotic resistance rates are proven to be very high. On the other hand, regions with lower level of antibiotic resistance (such as the region of Americas) are showing lower incidence of gastric cancer. 5 Despite this association, a causal relationship remains hard to infer mainly because the lack of surveillance systems for antibiotic-resistant HP does not allow to define actual incidence of antibiotic resistant infections. In countries where HP is highly endemic, the role of eradication treatment in reducing the incidence of gastric cancer has been widely acknowledged. 7, 8 Based on our data, we can hypothesize that this trend in reduction is expected to revert soon, since available treatment can no longer guarantee a satisfactory eradication rate.
Our meta-analysis has limitations. First, antibiotic resistance prevalence data were limited in several countries. An attempt to fill the gap in knowledge is being conducted by the Pan-European Registry on Helicobacter pylori Management, a multicenter, prospective, noninterventional register systematically collecting data from 30 European countries on prescribed regimen, compliance, outcome, and antibiotic resistance in order to produce descriptive studies of HP infection management. 35 Second, between-results heterogeneity among WHO regions and among different countries in the same WHO region is considerable. Sensitivity analysis by sorting the studies according to the countries provided a partial explanation of heterogeneity and further underlines the importance of implementing local antibiotic resistance surveillance. Another possible cause of study heterogeneity is different patterns of antibiotic consumption depending on the variable infectious disease burden in different geographical areas. A potential bias in data reporting, as demonstrated by the detection of significant publication bias, also constitutes a limitation in drawing overall pooled estimates from heterogeneous data. Third, several medium-to-high quality studies were conducted in a single medical center with a small sample size and might not be representative of the general population within a region.
Fourth, although studies suggest that culture-based tailored treatment are likely the best approach to minimize eradication failures, 36, 37 HP susceptibility testing is rarely performed despite the almost universal availability of culture facilities for other common pathogens. Austria (4) For more information, visit www.prisma-statement.org.
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